The Influx Healthtech IPO has seen considerable interest, with the IPO subscribed 9.18 times on the second day, June 19, 2025, as of 11:00 AM. The IPO, which opened for subscription on June 18, 2025, and closes on June 20, 2025, aims to raise ₹55.63 crores through a combination of a fresh issue of 46.94 lakh shares aggregating to ₹45.07 crores and an offer for sale of 11.00 lakh shares aggregating to ₹10.56 crores.
Subscription Status:
On Day 2, the retail category was subscribed 13.53 times, the QIB (Qualified Institutional Buyers) category 1.46 times, and the NII (Non-Institutional Investors) category 9.34 times. This demonstrates strong investor confidence across different categories. By 11:00 AM on Day 2, the IPO had received bids for 3,72,74,400 shares against the 40,58,400 shares on offer.
On the first day, the IPO was subscribed 5.86 times overall. Specifically, QIBs subscribed 1.46 times, NIIs 5.80 times, and RIIs (Retail Individual Investors) 8.40 times. The company received bids for 2,37,76,800 shares on the first day against the 40,58,400 shares available.
Grey Market Premium (GMP):
The Grey Market Premium (GMP) for Influx Healthtech's IPO was ₹40 on June 18, 2025, suggesting the IPO was trading at ₹136 in the grey market against the issue price of ₹96. Another source indicated a GMP of ₹42 as of 10:50 AM on June 18. The latest GMP figures indicated a listing price of ₹138 per share, which is a premium of 43.75% on the upper end of the price band. As of today, June 19, 2025, the GMP is ₹45.
It's important to note that the GMP is speculative and doesn't guarantee the stock's performance upon listing.
IPO Details:
Influx Healthtech's IPO has a price band of ₹91 to ₹96 per share, with a face value of ₹10. Retail investors need to apply for a minimum lot size of 1200 shares, requiring an investment of ₹1,15,200. High Net-Worth Individuals (HNIs) are required to bid for a minimum of two lots, totaling 2,400 shares, amounting to ₹2,30,400.
The IPO comprises a fresh issue of 46.94 lakh shares, worth ₹45.07 crore, and an offer-for-sale of 11 lakh shares, amounting to ₹10.56 crore.
Company Overview:
Founded in 2020, Influx Healthtech Limited is a healthcare-focused company specializing in contract manufacturing. It operates as a Contract Development and Manufacturing Organization (CDMO) and has manufacturing units in Thane, Maharashtra. The company manufactures dietary and nutritional supplements, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare items. Key clients include Bling Brands, Pursuit of Wellness, and others.
In FY25, the company reported revenue of ₹104.99 crores, compared to ₹100.10 crores in FY24. The profit after tax was ₹13.37 crores in FY25, up from ₹11.22 crores in FY24.
Utilization of Funds:
The funds raised through the IPO will be used to establish two new manufacturing facilities focused on nutraceuticals and veterinary segments, with an allocation of ₹34.19 crore. Proceeds will also be used to acquire machinery and for general corporate expenses.
Important Dates:
